Astellas Oncology pursues targeted therapies for hard-to-treat cancers with limited therapeutic options. Our pipeline includes novel compounds that focus on unmet medical needs.
|The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated. Information displayed is accurate as of May 2017.|
|Enzalutamide||Non-Metastatic Biochemical Recurrent PC|
|Enzalutamide||M1 Hormone-Sensitive Prostate Cancer|
|AMG 103 (Blinatumomab)||NHL / DLBCL|
|ASG-22ME (Enfortumab Vedotin)||Urothelial Cancer and Other Malignant Solid Tumors|
|AMG 103 (Blinatumomab)||Acute Lymphoblastic Leukemia|
|AGS67E||CLL / PLL / NHL / HCL|
Astellas Oncology is investigating Gilteritinib, a FLT3/AXL tyrosine kinase inhibitor in a clinical setting for the treatment of relapsed or refractory AML patients who have a FLT3 mutation that is seen in approximately 30 percent of AML patients.1
Gilteritinib compound exhibits inhibitory activity against the gene mutations FLT3-ITD, FLT3-TKD and AXL. A randomized Phase 3 trial of Gilteritinib at 120 mg per day in relapsed and refractory AML patients is underway.
Astellas Oncology is investigating a treatment for patients with advanced non-small cell lung cancer who are EGFR positive and are harboring T790M mutations, which cause acquired resistance to EGFR inhibitors in roughly 60 percent of NSCLC patients.2
ASP8273 is an orally available, irreversible, mutant-selective EGFR-TKI (epidermal growth factor receptor — tyrosine-kinase inhibitor) that inhibits the kinase activity of EGFR-activating mutations as well as the T790M resistance mutation.
The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated. Information displayed is accurate as of May 2017.
1 C. Chandra Kumar. "Genetic Abnormalities and Challenges in the Treatment of Acute Myeloid Leukemia." Genes & Cancer. 2011 Feb; 2(2): 95–107.
2 Collin M. Blakely and Trever G. Bivona. "Resiliency of lung cancers to EGFR inhibitor treatment unveiled offering opportunities to divide and conquer EGFR inhibitor resistance." Cancer Discovery. 2012 Oct; 2(10): 872–875.
Pfizer and Astellas are collaborating jointly to develop and commercialize enzalutamide. The companies are collaborating on a comprehensive development program that includes studies to develop enzalutamide across the full spectrum of advanced prostate cancer as well as other cancers. The companies jointly commercialize XTANDI® in the United States and Astellas has responsibility for manufacturing and all additional regulatory filings globally, as well as commercializing XTANDI® outside the United States.View clinical trials
Agensys, Inc., an affiliate of Astellas Pharma Inc., specializes in developing a pipeline of therapeutic fully human monoclonal antibodies (mAbs) to treat cancer. The mAb product pipeline is generated by Agensys' diverse portfolio of proprietary, clinically relevant targets that encompass unmet clinical needs in cancer. Multiple programs are currently undergoing Phase 1 and Phase 2 clinical trials.View clinical trials